FDI in Pharma: Greenfield Automatic, Brownfield Needs Govt Nod
Current · Source: Reserve Bank of India · RBI/2011-12/296 · issued 09 Dec 2011 · ~1 min read
Quick answerRBI has revised FDI rules for pharmaceuticals: 100% automatic route for greenfield investments continues, but brownfield investments (existing companies) now require government approval. AD Category-I banks must inform customers.
The rule, in the simplest words
100% FDI is allowed for greenfield pharma investments under automatic route.
Brownfield pharma investments (in existing companies) require government approval.
AD Category-I banks must inform customers about the new approval route for brownfield pharma investments.
How it plays out — a real example
A forex & trade-finance officer in Indore, Rohan, helps a foreign investor, Mr. Lee, set up a new pharma plant in India. Rohan ensures that the investment is classified as a greenfield project and can proceed under the automatic route. However, when Mr. Lee wants to invest in an existing Indian pharma company, Rohan informs him that the investment requires government approval under the brownfield route. Rohan advises Mr. Lee to obtain the necessary approvals before proceeding with the investment.
What changed
Previously, 100% FDI under automatic route was allowed for all pharma investments. Now, greenfield investments retain automatic approval, while brownfield investments (in existing companies) require government approval route.
What it means for you
Banks must ensure that brownfield pharma FDI proposals are routed through government approval, not automatic. This adds compliance checks for AD banks processing such investments. Greenfield deals remain straightforward under automatic route.
What you must do
Update internal FDI processing guidelines to distinguish greenfield vs brownfield pharma investments.
Advise customers that brownfield pharma FDI now requires government approval before remittance.
Ensure AD Category-I staff are trained on the new approval route for brownfield pharma investments.
Monitor and report brownfield pharma FDI applications separately to RBI as per revised norms.
Who it affects
AD Category-I banks processing pharma FDI, Foreign investors in Indian pharma companies, Indian pharma companies seeking brownfield FDI
❓ Common questions
What is the difference between greenfield and brownfield investments in pharma?
Greenfield means new investments (e.g., building new facilities), while brownfield means investments in existing companies (e.g., acquiring stakes).
Does this circular affect existing FDI approvals?
No, it applies to new investments. Existing approvals under earlier rules remain valid.
What should AD banks do if a customer applies for brownfield pharma FDI?
They must inform the customer that government approval is required and guide them to submit the application through the prescribed route.
📜 Read the original circular — full text as issued by RBI
RBI/2011-12/296
A. P. (DIR Series) Circular No.56
December 09, 2011
To
All Category-I Authorised Dealer Banks
Madam / Sir,
Foreign Investment in Pharmaceuticals Sector -
Amendment to the Foreign Direct Investment Scheme
Attention of Authorised Dealers Category – I (AD Category - I) banks is invited to the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident Outside India) Regulations, 2000, notified vide Notification No. FEMA 20/2000-RB dated May 3, 2000 , as amended from time to time. In terms of Schedule 1 of the Notification ibid , Foreign Direct Investment (FDI) up to 100 per cent is permitted in pharmaceuticals sector under the automatic route of the FDI Scheme.
2. The extant FDI policy for pharmaceuticals sector has since been reviewed and it has now been decided as under:
(i) FDI, up to 100 per cent, under the automatic route, would continue to be permitted for green field investments in the pharmaceuticals sector.
(ii) FDI, up to 100 per cent, would be permitted for brownfield investment (i.e. investments in existing companies), in the pharmaceutical sector, under the Government approval route.
3. A copy of Press Note 3 (2011Series) dated November 8, 2011 issued in this regard is enclosed.
4. AD Category - I banks may bring the contents of the circular to the notice of their customers/constituents concerned.
5. Necessary amendments to the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) Regulations, 2000 (Notification No. FEMA 20/2000-RB dated May 3, 2000) are being notified separately.
6. The directions contained in this circular have been issued under Sections 10(4) and 11(1) of the Foreign Exchange Management Act, 1999 (42 of 1999) and are without prejudice to permissions / approvals, if any, required under any other law.
Yours faithfully,
(Rashmi Fauzdar)
Chief General Manager
Reproduced for reference with acknowledgment — Source: Reserve Bank of India · RBI/2011-12/296 · issued 09 Dec 2011. The plain-English explanation above is BankPulse’s own independent summary.
Monitor and report brownfield pharma FDI applications separately to RBI as per revised norms.
📜 Compliance
Update internal FDI processing guidelines to distinguish greenfield vs brownfield pharma investments.
Advise customers that brownfield pharma FDI now requires government approval before remittance.
Ensure AD Category-I staff are trained on the new approval route for brownfield pharma investments.
Grouped from the action items above — a single circular may involve more than one team.
Worked example & action-note template
Example: if you are a Compliance officer at a bank this circular applies to (AD Category-I banks processing pharma FDI, Foreign investors in Indian pharma companies, Indian pharma companies seeking brownfield FDI), your first concrete step on “FDI in Pharma: Greenfield Automatic, Brownfield Needs Govt Nod” is: “Update internal FDI processing guidelines to distinguish greenfield vs brownfield pharma investments.” (RBI issued this 09 Dec 2011).
Action required: Update internal FDI processing guidelines to distinguish greenfield vs brownfield pharma investments.
Action required: Advise customers that brownfield pharma FDI now requires government approval before remittance.
Action required: Ensure AD Category-I staff are trained on the new approval route for brownfield pharma investments.
Action required: Monitor and report brownfield pharma FDI applications separately to RBI as per revised norms.
Owner: ____________ Target date: ____________
Board/committee approval needed? Y / N
Evidence filed in compliance register on: ____________
Built only from this circular’s own published fields — not legal advice; always confirm against the official RBI source.
💬 Banker Discussion
Discuss this circular with fellow bankers — reply, upvote what helps, report what doesn’t belong. Be professional; no client data. Views are the commenter’s own, not BankPulse’s.
BankPulse Compliance Evidence Pack — generated 03 Aug 2026 · status cross-checked against RBI’s official withdrawal register (refreshed weekly). Official RBI source: https://www.rbi.org.in/Scripts/NotificationUser.aspx?Id=6868&Mode=0 — Plain-English summary by BankPulse (bankpulse.ai), reviewed by our expert reviewer, CA Amit Jain. Independent platform, not affiliated with the Reserve Bank of India; is our own plain-English paraphrase, not RBI’s original wording.
Help us keep this accurate
Found an inaccuracy or have an improvement? Tell us. Every report is reviewed by our team before any change is made — nothing goes live unverified.
Public beta — plain-English informational summaries. Always verify against the official RBI source (circular number cited on every page) before making compliance, credit, treasury, audit, or operational decisions. · Join our WhatsApp channel ↗
BANKPULSE · FREE DAILY BRIEF
Get RBI updates for your role
Every important RBI update, decoded in plain English — for your career, exams & financial awareness.
We collect only your email, name and role, used solely to send your brief — never sold or shared. Withdraw anytime via the unsubscribe link in any email. Independent platform, not affiliated with the RBI. Information, not legal advice.
REPORT AN ERROR · BETA
Spotted an error? Earn 500 BankPulse Credits
Help us stay accurate. If your correction is verified true and approved by our founder, you earn 500 BankPulse Credits — redeemable when the platform monetises.
Reviewed by a human before any credit is awarded. We never change the site from crowd input without verification.
WANT A NEW FEATURE · BETA
What would make BankPulse more useful for you?
Tell us what to build next — a tool, a data view, a role page, anything. We read every suggestion.
Thank you — your ideas directly shape what we build.